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Objectives: Multiple myeloma (MM) is known as an incurable cancer of plasma 
cells, which incurs significant burden on patients. There are estimated 27,000 MM 
patients in China in 2013, and the incidence is 1–4 per 100,000 people per year. 
However, the disease burden of MM in China has not been well studied. Using 
Guangzhou claim data, this article estimated the economic burden on patients with 
MM from a societal perspective. MethOds: 2009-2011 databases of Urban Employee 
Basic Medical Insurance and Urban Residents Basic Medical Insurance were used to 
estimate the direct medical cost of MM and the determinants of medical cost. The 
direct medical costs of bortezomib-based therapies and regular chemotherapies 
were compared. Disability Adjusted Life Year (DALY) was used to estimate the indi-
rect cost. Results: For a patients with MM conditions in Guangzhou, the direct cost 
was RMB 8.45 million in 2009, 8.52 million in 2010, and 13.90 million in 2011, while 
the indirect cost was RMB 12.18 million, 13.11 million, and 19.46 million, respectively. 
Moreover, the MM medical cost was higher with age, increasing reimbursement 
rate and length of stay. The average hospitalization expenditure for bortezomib-
based therapies and regular chemotherapies were RMB 60,945.84±38,335.12 and 
16,465.62±19,695.13 (P< 0.001). The out-of-pocket (OOP) cost for per treatment cycle 
were significantly higher for patients treated with bortezomib-based therapy (RMB 
43,773.57±12,415.07) than for those treated with regular chemotherapies (RMB 
3,720.74±4,060.65). cOnclusiOns: MM conditions have serious economic burdens, 
and was significantly increased overtime in China.MM patients would pay over 12 
times more OOP cost for the use of bortizomib-based therapy than for the use of 
commonly-used chemotherapies.
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Objectives: To investigate the health care utilization and cost, focusing on the use 
of oral anti-diabetic drugs (OADs) for type 2 diabetes patients in China. MethOds: 
A large scale, prospective, and observational study was conducted in 5 cities of 
China. Subjects on any OAD were enrolled. The data was collected from longitu-
dinal interviews and diary following-up with the enrolled patients. Primary data 
information included socio-demographic characteristics, health care and medica-
tion utilization and costs, laboratory assessments, and quality of life. The baseline 
interview and 4 times of following-up were conducted within 12 months. HbA1c, 
fasting blood-glucose and blood lipids were assessed. Multivariable regression and 
propensity score matching methods were used to control for confounding factors 
in the study. Results: 2886 patients enrolled at baseline, 2322 of them completed 
the full study. The average age of enrolled patients at baseline was 61.71(sd= 11.27) 
years. The number of OADs per patient was 1.66 (sd= 0.80) with a median of 2. The 
mostly used 4 OADs are: Metformin (44.01%), Acarbose (28.64%), XIaoke Pill (a tra-
ditional Chinese medicine, 20.54%) and Gliclazide (18.26%). On average, a patient 
spent CNY 8,867.56 (sd= 17,642.51) on health care annually, where OADs cost CNY 
2,645.82 (sd= 3,123.30). When controlling for other confounding variables via statisti-
cal models, further analysis finds that patients on XIaoke Pill as the major regimen 
ended up with a reduction in total health care cost by CNY 2,151 (p< 0.01), where 
OADs cost was reduced by about CNY 626 (p< 0.01). cOnclusiOns: Type 2 Diabetes 
patients in China bear a heavy economic burden. Among OADs, traditional Chinese 
medicine Xiaoke Pill appears to be a quite cost effective treatment regimen for 
diabetic patients in China. Future analysis is warranted to investigate mechanisms 
and conditions through which oral Chinese OADs may be cost effective for some 
diabetic patients in China.
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Objectives: To describe the methodologies used in health economics (HE) studies 
on Parkinson’s disease (PD) in China. MethOds: A structured literature review was 
conducted to describe the methodology used to generate HE evidence for PD treat-
ment in China. The review was conducted in both English and Mandarin languages 
using four databases: PubMed, Cochrane, WAN FANG and VIP, for articles published 
between 2000 and 2013. Study selection was limited to Chinese population based 
in China and those which reported cost-effectiveness ratio (CER) or incremental 
cost-effectiveness ratio (ICER) of PD pharmacotherapy. Results: Six studies were 
selected, all in mandarin. The studies were conducted using different study designs 
including cohort, randomised controlled trials (RCT) and retrospective observation. 
None of the studies utilised any HE modelling. Cost-effectiveness comparisons were 
made between levodopa monotherapy with or without benserazide against other 
adjuvant PD pharmacotherapies. Two studies were conducted based on health sys-
tem perspectives, 2 studies on societal perspectives and the remaining 2 studies 
did not report any. Cost components calculated differed between studies. Only 2 
studies investigated the cost-effectiveness of PD treatment using both direct and 
indirect costs. The effectiveness outcomes were mostly determined using either 
Unified Parkinson’s disease Rating Scale (UPDRS), followed by Parkinson’s disease 
Questionnaire (PDQ) or Visual Analogue Quality of Life (VAS-QOL) scale. Only one 
study reported ICER value whereas the remaining studies only reported CER. All 
studies conducted primary data collection for the purpose of the cost-effectiveness 
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Objectives: Being from the very land and a son of the same soil. Africa is the 
world’s second-largest also the most poorest most underdeveloped continent. 
With great struggles and constraints in provision of essential drugs and program 
initiatives,its hard to make proper intervention in urgent essential needs of rem-
edies required on a daily basis especially in the wider scope of village population 
on health priorities. MethOds: In 2007, Africa’s dialysis population constituted 
only 4.5% of the world’s dialysis population, with a prevalence of 74 per million 
population (pmp), compared to a global average of 250 pmp. In almost half the 
African countries, no dialysis patients are reported. The prevalence of peritoneal 
dialysis (PD) was 2.2 pmp, compared to a global prevalence of 27 pmp, with the bulk 
of African PD patients (85%) residing in South Africa. In North African countries, 
which serve 93% of the Results: African dialysis population, the contribution of 
PD to dialysis is only 0% – 3%. Cost is a major factor affecting the provision of 
dialysis treatment and many countries are forced to ration dialysis therapy. Rural 
setting, difficult transportation, low electrification rates, limited access to improved 
sanitation and improved water sources, unsuitable living circumstances, and the 
limited number of nephrologists are obstacles to the provision of PD in many coun-
tries. cOnclusiOns: The potential for successful regular PD programs in tropical 
countries has now been well established. Cost is a major prohibitive factor but the 
role of domestic manufacture in facilitating widespread use of PD is evidenced by 
the South African example. Education and training are direly needed and these are 
areas where international societies can be of great help.
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Objectives: Though Chinese herbal medicine had been proofed effective in clinical 
practice, due to the lack of suitable outcomes, the current randomised controlled 
trial studies (RCT) mostly stated that Chinese herbal formulas uneffective, thus the 
effectiveness are rarely confirmed publicly. In this study we applied Chinese syn-
dromes in the effectiveness evaluation of Chinese herbal formulas and to assess their 
suitability and necessity. MethOds: In an finished RCT research, angina patients 
with Phlegm and Blood stasis syndrome were randomized into experimental group 
(Chinese herbal formulas combined with western basic therapy) and placebo group 
respectively. An Chinese questionnaire TCM-SAQ, Seattle Angina Questionnaire (SAQ), 
and SF-12 were applied as patients reported outcomes to evaluate the effectiveness. 
And the results shows that there is no statistical difference in SF-12 and SAQ between 
two groups after 8 weeks’ treatment, while there is significant difference shown in 
the syndrome domain of TCM-SAQ. On the basis of these results, the deviation value 
of all the domains in each questionnaire from the baseline to after 8 weeks’ treat-
ment were calculated. And then the Pearson correlation of the deviation value among 
the domains in TCM-SAQ with domains in SAQ and SF-12 were analysed. Results: 
The correlation between angina domain in TCM-SAQ with each domain in SAQ and 
SF-12 is from 0.045 to 0.237 (p< 0.01), physical limitation domain is 0.450 to 0.779 
(p< 0.01), sleep quality domain is 0.342 to 0.555(p< 0.01), Chinese syndrome domain is 
0.477 to 0.688 (p< 0.01), worry of disease domain is 0.439 to 0.709 (p< 0.01), treatment 
satisfaction domain is 0.298 to 0.689 (p< 0.01). For Chinese syndrome domain the 
correlation with domains in SAQ and SF-12 were all higher than 0.4 and lower than 
0.7. cOnclusiOns: As an patients reported outcome, Chinese syndrome can reflect 
the effectiveness of Chinese herbal formulas. And it is in some degree suitable and 
necessary in the effectiveness evaluation of Chinese herbal formulas.
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Objectives: The common comorbidity indexes was developed about two dec-
ades ago and were not appropriate for inpatients risk adjustment nowadays. Our 
objective was to develop a risk stratification model that broadly predicts mortality 
risks in hospitalized patients with circulatory system diseases. MethOds: The 
risk score model was generated by using inpatient summary report of electronic 
medical record dataset from 2006 to 2010 among 50 tertiary hospitals in Beijing, 
and validated by same dataset of 65 tertiary hospitals in the whole country in 
2012. The patient diagnosis as identified by using the International Classification of 
Diseases, 10th Revision. Risk score was developed with individual major diagnostic 
codes. Receiver operating characteristic (ROC) analysis was used to evaluated the 
predictive effect of risk score, and the Charlson Comorbidity Index (CCI) was used 
to compare with the risk score in validation data sets. Results: The diagnosis code 
of total 4,216,375 patients were used to generate the risk scores which comprise 293 
items out of more than 4,000 categories and ranged from 96 to 1. In the validation 
data set, the ROC was 0.845 compared with the CCI ROC of 0.748 among myocardial 
infarction inpatients, and in coronary artery bypass grafting(CABG) inpatients the 
ROC was 0.729 to CCI ROC of 0.626, in percutaneous coronary intervention(PCI) 
inpatients the ROC was 0.847 and 0.648 respectively. The ROC of novel risk score 
was improved 12.7, 16.4 and 30.1 percent among inpatients with circulatory system 
disease. cOnclusiOns: This study generated a broadly applicable tool for risk 
adjustment that predicts circulatory system diseases inpatient mortality with more 
reliability than current risk indexes. This risk index will allow comorbidity-adjusted 
outcomes broadly in surgery, hospitalization and drug efficacy evaluation.
